

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Non-Preferred Very High Potency (Group 1) Topical Corticosteroids

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Comment	Quantity Limit
Clobetasol 0.05% cream/gel/ointment/solution	Preferred	May be subject to quantity limit
Clobetasol emollient 0.05% cream		
Halobetasol 0.05% cream/ointment		
Cormax 0.05% solution		
Augmented betamethasone dipropionate 0.05% ointment/lotion/gel	Non-Preferred	
Clobex 0.05% lotion/spray/shampoo		
Clodan 0.05% shampoo/kit		
Clobetasol 0.05% foam/lotion/shampoo/spray		
Clobetasol-E 0.05% foam		
Cordran tape 4 mcg/cm ²		
Diprolene 0.05% ointment		
Fluocinonide 0.1% cream		
Halobetasol 0.05% foam		
Lexette 0.05% foam		
Olux 0.05% foam		
Olux-E 0.05% foam		
Temovate 0.05% cream/ointment		
Temovate emollient 0.05% cream		
Tovet 0.05% foam		
Ultravate 0.05% cream/ointment/lotion		
Vanos 0.1% cream		

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

APPROVAL CRITERIA

Requests for a non-preferred very high potency topical corticosteroid may be approved when the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to two preferred very high potency topical corticosteroids; **OR**
- II. The preferred agents are not FDA-approved for the prescribed indication and the requested non-preferred agent is; **OR**
- III. The preferred agents are not acceptable due to concomitant clinical situations, including but not limited to the following:
 - A. Individual requires an alternate dosage form; **OR**
 - B. Individual has a confirmed hypersensitivity to preferred agent(s) or class of agents.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 3, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. Torres MJ, Canto G. Hypersensitivity reactions to corticosteroids. *Curr Opin Allergy Clin Immunol* 2010; 10:273.

PAGE 2 of 3 07/17/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

6. Goldstein BG, Goldstein AO. Topical corticosteroids: Use and adverse effects. [Comparison of representative topical corticosteroid preparations (classified according to the US system)]. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <https://www.uptodate.com> (Accessed on January 15, 2020.)

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.